investorscraft@gmail.com

Investor's Craft

Stock Screeners
Stock Indices
Stock Valuation

Intrinsic Value of Merck & Co., Inc. (MRK)

Previous Close$101.77
Intrinsic Value$42.00
Upside potential  -59%
Previous Close
$101.77
Intrinsic Value
$42.00*
Potential        
-59%

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2022-12-31 and quarterly data as of 2023-06-30.

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

Intrinsic Value Stock Screener
Artificial intelligence value of

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2022(a)2023202420252026202720282029203020312032203320342035203620372038203920402041204220432044204520462047

INCOME STATEMENT

Revenue growth rate, %21.7NaN
Revenue, $59283NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m41001NaN
Operating income, $m18282NaN
EBITDA, $m22191NaN
Interest expense (income), $mNaN
Earnings before tax, $m16437NaN
Tax expense, $m1918NaN
Net income, $m14519NaN

BALANCE SHEET

Cash and short-term investments, $m13192NaN
Total assets, $m109160NaN
Adjusted assets (=assets-cash), $m95968NaN
Average production assets, $m63186NaN
Working capital, $m11483NaN
Total debt, $m30972NaN
Total liabilities, $m63102NaN
Total equity, $m46058NaN
Debt-to-equity ratio0.672NaN
Adjusted equity ratio0.366NaN

CASH FLOW

Net income, $m14519NaN
Depreciation, amort., depletion, $m3909NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m19095NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-4388NaN
Free cash flow, $m23483NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m11483
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN

Company description

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
HomeMenuAccount